Assessing the direct medical costs of treating patients with cancer in Kenya: a pilot study - findings and implications for the future

Omondi Michelle Atieno, Sylvia Opanga, Amanj Kurdi, Antony P Martin, Brian Godman

Research output: Contribution to conferenceAbstract

Abstract

Abstract
Background. The economic burden of cancer is a major issue across countries with the majority of cancer deaths in middle-income and low-income countries where there are appreciable concerns with funding of care. In Kenya, most patients pay out of pocket, and even those who are insured are not properly covered to cover the full costs of cacer treatment, placing a considerable burden on the family if members develop cancer. However, the actual cost of cancer treatment in Kenya has not been enumerated before. This is essential to inform future government as the health system evolves in Kenya. Objectives: To evaluate the economic burden of the treatment of cancer patients in a leading hospital in Kenya. Method: Descriptive cross-sectional cost of illness study over a one year period (2016) in the leading teaching and referral hospital in Kenya, with data collected from hospital files of randomly sampled adult patients between January and March 2017. Outcomes included direct medical costs for managing cancer (chemotherapy, surgery, radiotherapy). Results. The cost of cancer therapy is highly dependent on the cancer modality. Of the 412 patients included, most cancer patients had surgery (25.4%), followed by chemotherapy (4.6%) and palliative care (21.7%). The most prevalent male cancer were prostate cancer (9.7%, n=40) and colon cancer (2.9%, n=12); while female cancers were mostly cervical cancer (23.78%, n=98) and breast cancer (7.28%, n=30). The cost of cancer therapy varied with the type of cancer and its stage. Patients on chemotherapy alone cost an average of KES 138,206 (1US$ = KES 100) for the year; while those treated with surgery only cost an average of KES 128,207, and those on radiotherapy alone used KES 119,035. Some patients had a combination of all three costing on average KES 333,462 per patient. Conclusion: The cost of cancer treatment in Kenya depends on the type of cancer, the modality, cost of medicines and the type of inpatient admission. The greatest contributors to the cost of cancer care are the cost of medicines and inpatient admissions. Pressure needs to be applied to the Government and insurance companies to ease out-of-pocket payments especially for mediciens.

Conference

Conference34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
CountryCzech Republic
CityPrague
Period22/08/1826/08/18

Fingerprint

Kenya
Costs and Cost Analysis
Neoplasms
Health Care Costs
Drug Therapy
Inpatients
Prostatic Neoplasms
Radiotherapy
Economics
Cost of Illness
Health Expenditures
Insurance
Palliative Care
Teaching Hospitals
Uterine Cervical Neoplasms
Colonic Neoplasms

Keywords

  • pharmacoeconomics
  • cancer treatments
  • Kenya

Cite this

Atieno, O. M., Opanga, S., Kurdi, A., Martin, A. P., & Godman, B. (2018). Assessing the direct medical costs of treating patients with cancer in Kenya: a pilot study - findings and implications for the future. Abstract from 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic.
Atieno, Omondi Michelle ; Opanga, Sylvia ; Kurdi, Amanj ; Martin, Antony P ; Godman, Brian. / Assessing the direct medical costs of treating patients with cancer in Kenya : a pilot study - findings and implications for the future. Abstract from 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic.1 p.
@conference{772c24fc0f794b599dc52f040fa9a701,
title = "Assessing the direct medical costs of treating patients with cancer in Kenya: a pilot study - findings and implications for the future",
abstract = "AbstractBackground. The economic burden of cancer is a major issue across countries with the majority of cancer deaths in middle-income and low-income countries where there are appreciable concerns with funding of care. In Kenya, most patients pay out of pocket, and even those who are insured are not properly covered to cover the full costs of cacer treatment, placing a considerable burden on the family if members develop cancer. However, the actual cost of cancer treatment in Kenya has not been enumerated before. This is essential to inform future government as the health system evolves in Kenya. Objectives: To evaluate the economic burden of the treatment of cancer patients in a leading hospital in Kenya. Method: Descriptive cross-sectional cost of illness study over a one year period (2016) in the leading teaching and referral hospital in Kenya, with data collected from hospital files of randomly sampled adult patients between January and March 2017. Outcomes included direct medical costs for managing cancer (chemotherapy, surgery, radiotherapy). Results. The cost of cancer therapy is highly dependent on the cancer modality. Of the 412 patients included, most cancer patients had surgery (25.4{\%}), followed by chemotherapy (4.6{\%}) and palliative care (21.7{\%}). The most prevalent male cancer were prostate cancer (9.7{\%}, n=40) and colon cancer (2.9{\%}, n=12); while female cancers were mostly cervical cancer (23.78{\%}, n=98) and breast cancer (7.28{\%}, n=30). The cost of cancer therapy varied with the type of cancer and its stage. Patients on chemotherapy alone cost an average of KES 138,206 (1US$ = KES 100) for the year; while those treated with surgery only cost an average of KES 128,207, and those on radiotherapy alone used KES 119,035. Some patients had a combination of all three costing on average KES 333,462 per patient. Conclusion: The cost of cancer treatment in Kenya depends on the type of cancer, the modality, cost of medicines and the type of inpatient admission. The greatest contributors to the cost of cancer care are the cost of medicines and inpatient admissions. Pressure needs to be applied to the Government and insurance companies to ease out-of-pocket payments especially for mediciens.",
keywords = "pharmacoeconomics, cancer treatments, Kenya",
author = "Atieno, {Omondi Michelle} and Sylvia Opanga and Amanj Kurdi and Martin, {Antony P} and Brian Godman",
year = "2018",
month = "8",
day = "28",
language = "English",
note = "34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management ; Conference date: 22-08-2018 Through 26-08-2018",

}

Atieno, OM, Opanga, S, Kurdi, A, Martin, AP & Godman, B 2018, 'Assessing the direct medical costs of treating patients with cancer in Kenya: a pilot study - findings and implications for the future' 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic, 22/08/18 - 26/08/18, .

Assessing the direct medical costs of treating patients with cancer in Kenya : a pilot study - findings and implications for the future. / Atieno, Omondi Michelle ; Opanga, Sylvia; Kurdi, Amanj; Martin, Antony P; Godman, Brian.

2018. Abstract from 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic.

Research output: Contribution to conferenceAbstract

TY - CONF

T1 - Assessing the direct medical costs of treating patients with cancer in Kenya

T2 - a pilot study - findings and implications for the future

AU - Atieno, Omondi Michelle

AU - Opanga, Sylvia

AU - Kurdi, Amanj

AU - Martin, Antony P

AU - Godman, Brian

PY - 2018/8/28

Y1 - 2018/8/28

N2 - AbstractBackground. The economic burden of cancer is a major issue across countries with the majority of cancer deaths in middle-income and low-income countries where there are appreciable concerns with funding of care. In Kenya, most patients pay out of pocket, and even those who are insured are not properly covered to cover the full costs of cacer treatment, placing a considerable burden on the family if members develop cancer. However, the actual cost of cancer treatment in Kenya has not been enumerated before. This is essential to inform future government as the health system evolves in Kenya. Objectives: To evaluate the economic burden of the treatment of cancer patients in a leading hospital in Kenya. Method: Descriptive cross-sectional cost of illness study over a one year period (2016) in the leading teaching and referral hospital in Kenya, with data collected from hospital files of randomly sampled adult patients between January and March 2017. Outcomes included direct medical costs for managing cancer (chemotherapy, surgery, radiotherapy). Results. The cost of cancer therapy is highly dependent on the cancer modality. Of the 412 patients included, most cancer patients had surgery (25.4%), followed by chemotherapy (4.6%) and palliative care (21.7%). The most prevalent male cancer were prostate cancer (9.7%, n=40) and colon cancer (2.9%, n=12); while female cancers were mostly cervical cancer (23.78%, n=98) and breast cancer (7.28%, n=30). The cost of cancer therapy varied with the type of cancer and its stage. Patients on chemotherapy alone cost an average of KES 138,206 (1US$ = KES 100) for the year; while those treated with surgery only cost an average of KES 128,207, and those on radiotherapy alone used KES 119,035. Some patients had a combination of all three costing on average KES 333,462 per patient. Conclusion: The cost of cancer treatment in Kenya depends on the type of cancer, the modality, cost of medicines and the type of inpatient admission. The greatest contributors to the cost of cancer care are the cost of medicines and inpatient admissions. Pressure needs to be applied to the Government and insurance companies to ease out-of-pocket payments especially for mediciens.

AB - AbstractBackground. The economic burden of cancer is a major issue across countries with the majority of cancer deaths in middle-income and low-income countries where there are appreciable concerns with funding of care. In Kenya, most patients pay out of pocket, and even those who are insured are not properly covered to cover the full costs of cacer treatment, placing a considerable burden on the family if members develop cancer. However, the actual cost of cancer treatment in Kenya has not been enumerated before. This is essential to inform future government as the health system evolves in Kenya. Objectives: To evaluate the economic burden of the treatment of cancer patients in a leading hospital in Kenya. Method: Descriptive cross-sectional cost of illness study over a one year period (2016) in the leading teaching and referral hospital in Kenya, with data collected from hospital files of randomly sampled adult patients between January and March 2017. Outcomes included direct medical costs for managing cancer (chemotherapy, surgery, radiotherapy). Results. The cost of cancer therapy is highly dependent on the cancer modality. Of the 412 patients included, most cancer patients had surgery (25.4%), followed by chemotherapy (4.6%) and palliative care (21.7%). The most prevalent male cancer were prostate cancer (9.7%, n=40) and colon cancer (2.9%, n=12); while female cancers were mostly cervical cancer (23.78%, n=98) and breast cancer (7.28%, n=30). The cost of cancer therapy varied with the type of cancer and its stage. Patients on chemotherapy alone cost an average of KES 138,206 (1US$ = KES 100) for the year; while those treated with surgery only cost an average of KES 128,207, and those on radiotherapy alone used KES 119,035. Some patients had a combination of all three costing on average KES 333,462 per patient. Conclusion: The cost of cancer treatment in Kenya depends on the type of cancer, the modality, cost of medicines and the type of inpatient admission. The greatest contributors to the cost of cancer care are the cost of medicines and inpatient admissions. Pressure needs to be applied to the Government and insurance companies to ease out-of-pocket payments especially for mediciens.

KW - pharmacoeconomics

KW - cancer treatments

KW - Kenya

UR - https://www.pharmacoepi.org/meetings/annual-conference/2018-icpe/

M3 - Abstract

ER -

Atieno OM, Opanga S, Kurdi A, Martin AP, Godman B. Assessing the direct medical costs of treating patients with cancer in Kenya: a pilot study - findings and implications for the future. 2018. Abstract from 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic.